Volume 24, Number 9—September 2018
Research Letter
Wohlfahrtiimonas chitiniclastica Bacteremia in Hospitalized Homeless Man with Squamous Cell Carcinoma
Yuichi Katanami
, Satoshi Kutsuna, Maki Nagashima, Saho Takaya, Kei Yamamoto, Nozomi Takeshita, Kayoko Hayakawa, Yasuyuki Kato, Shuzo Kanagawa, and Norio Ohmagari
, Satoshi Kutsuna, Maki Nagashima, Saho Takaya, Kei Yamamoto, Nozomi Takeshita, Kayoko Hayakawa, Yasuyuki Kato, Shuzo Kanagawa, and Norio Ohmagari
Table
Antimicrobial susceptibility profile of Wohlfahrtiimonas chitiniclastica from a blood culture from a patient treated at the National Center for Global Health and Medicine, Tokyo, Japan, 2016.
| Antimicrobial drug | MIC, mg/L susceptibility profile |
|---|---|
| Piperacillin | ≤8, S |
| Piperacillin/tazobactam | ≤8, S |
| Ceftazidime | ≤4, S |
| Cefepime | ≤2, S |
| Aztreonam | ≤4, S |
| Imipenem/cilastatin | ≤1, S |
| Meropenem | ≤1, S |
| Amikacin | ≤8, S |
| Gentamicin | ≤2, S |
| Tobramycin | ≤2, S |
| Minocycline | ≤2, S |
| Levofloxacin | 1, S |
| Ciprofloxacin | 1, S |
| Trimethoprim/sulfamethoxazole | ≤2, S |
*S, susceptible.
Page created: August 30, 2018
Page updated: August 30, 2018
Page reviewed: August 30, 2018
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.